Company Overview - Baxter International manufactures essential medical products such as surgical sealants and hospital beds, which are crucial for the healthcare industry [2] - The aging baby boomer generation is expected to increase demand for healthcare, thereby boosting demand for Baxter's products [2] Recent Performance - Baxter has faced inconsistent revenue and has reported losses, leading to a significant stock decline of approximately 75% over the past five years [5] - The company recently cut its dividend from $0.17 per share per quarter to a token penny, reflecting its current financial struggles [1][5] Investment Considerations - Despite recent challenges, Baxter's products are deemed necessary, suggesting the company may navigate through its current difficulties [5] - The company maintains a manageable level of debt, covering its interest costs two times over, which provides some financial stability [5] - The stock's valuation appears attractive, with price-to-sales and price-to-book ratios below their five-year averages, indicating it may be undervalued [6] Future Outlook - There is potential for turnaround investors to find value in Baxter, as the demand for its products is expected to grow in the long term [7] - However, recovery may take time and could be uneven, particularly given the recent dividend cut which may deter income-focused investors [7]

Group 1 - Pzena Focused Value Strategy underperformed the Russell 1000® Value Index in Q4 2025, with a net return of 2.5% compared to the Index's 3.8% [1] - The firm identifies appealing valuation differences in the current market environment, which is seen as favorable for long-term value investors [1] - Baxter International Inc. (NYSE:BAX) was highlighted as a leading performance detractor, with a one-month return of -3.31% and a 52-week loss of 36.76% [2] Group 2 - Baxter's stock closed at $19.87 per share on February 2, 2026, with a market capitalization of $10.214 billion [2] - The healthcare sector, including Baxter, faced challenges due to disappointing third-quarter results and a dividend cut, alongside delayed normalization of IV fluid volumes [2] - The number of hedge funds holding Baxter increased from 31 to 38 in the third quarter, indicating growing interest despite its underperformance [3]

Core Viewpoint - Baxter International Inc. will host a conference call to discuss its fourth-quarter 2025 financial results on February 12, 2026, at 7:30 a.m. Central Time [1] Group 1 - The conference call will be accessible via a pre-registration link and will also be webcasted on Baxter's website [1][2] - The call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting [2] Group 2 - Baxter is a leading global medtech company with a mission to provide essential healthcare solutions across various settings [3] - The company has approximately 38,000 team members dedicated to saving and sustaining lives through its portfolio of connected solutions and medical devices [3] - Baxter has been a trusted partner in healthcare for nearly a century, impacting millions of patients and healthcare providers [3]

Company Overview - Baxter International Inc. has a market cap of $10.3 billion and offers a wide range of medical products, pharmaceuticals, and healthcare technologies used in various settings including hospitals and home care [1] - The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals, serving a global customer base [1] Financial Performance - Analysts expect Baxter to report an adjusted EPS of $0.53 for fiscal Q4 2025, reflecting an 8.6% decline from $0.58 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $2.36, indicating a growth of 24.9% from $1.89 in fiscal 2024 [3] Stock Performance - Baxter's stock has decreased by 35% over the past 52 weeks, underperforming the S&P 500 Index, which rose by 16.9%, and the State Street Health Care Select Sector SPDR ETF, which gained 10.4% during the same period [4] - Despite reporting a better-than-expected Q3 2025 adjusted EPS of $0.69, the stock plunged 14.5% due to revenue of $2.84 billion missing forecasts [5] Guidance and Analyst Ratings - The company has cut its full-year adjusted EPS guidance to a range of $2.35 - $2.40 and reduced expected sales growth to 4% - 5% due to disruptions at its North Cove facility and issues with its infusion pump portfolio [5] - Analysts maintain a cautious consensus rating on Baxter's stock, with 2 "Strong Buys," 13 "Holds," and 1 "Moderate Sell," reflecting a slight decrease in bullish sentiment compared to three months ago [6] - The average analyst price target for Baxter is $21.71, suggesting a potential upside of nearly 8% from current levels [6]

Core Insights - The article highlights the investment strategies and achievements of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and the development of a system called "Victory Formation" for identifying stocks based on supply/demand imbalances [1]. Group 1: Investment Strategies - Paul Franke recommends a diversified approach by owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1]. - The "Bottom Fishing Club" articles focus on deep value candidates or stocks that are experiencing a significant reversal in technical momentum [1]. - The "Volume Breakout Report" articles discuss positive trend changes supported by strong price and volume trading action [1]. Group 2: Performance and Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and was recognized for his stock market and commodity macro views [1]. - He achieved a top ranking in the Motley Fool® CAPS stock picking contest during parts of 2008 and 2009, out of over 60,000 portfolios [1]. - As of December 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance based on suggestions made over the last five years [1].

Company Overview - Baxter International Inc. (BAX) is set to launch its Dynamo Series smart stretcher in the U.S., enhancing its portfolio of connected care solutions for hospital environments [1][8] - The stretcher aims to support care teams in high-pressure settings while improving patient safety, comfort, and workflow efficiency [1][4] Product Features - The Dynamo Series stretcher features an electric design that reduces patient transfers, incorporates fall-prevention technology, and offers flexible positioning options for various procedures [8][9] - It includes advanced safety features such as the SafeView+ system for visual safety cues and a three-mode bed exit alarm for real-time alerts [10] - The stretcher provides one of the widest care surfaces in its category, enhancing stability and comfort for patients of different sizes [11] Strategic Focus - The launch reflects Baxter's commitment to practical innovation in acute care, particularly in emergency and perioperative settings [2] - The Dynamo Series is part of Baxter's strategy to strengthen its Care & Connectivity segment with technology-enabled products that address clinical challenges [2][4] Market Context - Baxter's market capitalization currently stands at $10.36 billion [6] - The global smart hospital beds market is projected to grow from $523.7 million in 2024 to $1 billion by 2034, with a CAGR of 7.3%, driven by demand for patient-centered care and hospital automation [12] Stock Performance - Following the announcement of the Dynamo Series, BAX shares traded flat in the after-market session, having lost 31.1% over the past six months compared to a 7.2% decline in the industry [3]

Core Viewpoint - Baxter is undergoing a leadership transition with Andrew Hider as the new CEO, emphasizing continuous improvement and operational excellence as key components of the company's strategy [2][3]. Company Overview - Baxter is recognized as an iconic brand in the medical technology sector, aiming to deliver high value to its customers [3]. - The company has significant opportunities for improvement and growth in various areas [3]. Leadership Background - Andrew Hider has a diverse background in the industry, having worked at General Electric and Danaher Corporation, where he managed multiple companies across different sectors [2]. - Hider has been with Baxter for five months and is focused on leveraging his experience to enhance the company's operations [2].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Summary of Baxter International FY Conference Call Company Overview - **Company**: Baxter International (NYSE:BAX) - **CEO**: Andrew Hider, who has been in the role for five months - **Revenue**: Over $11 billion, with 55% from the United States and the remainder from international markets - **Employees**: Over 38,000 across more than 40 manufacturing locations - **Patient Reach**: Serves over 350 million patients annually in over 100 countries [2][3] Core Business Segments - **Operating Segments**: - Medical Products and Therapies - Healthcare Systems and Technologies - Pharmaceuticals - **Key Products**: - Infusion therapies, IV solutions, and surgical technologies - Connected healthcare solutions and patient monitoring systems - Specialty injectables and inhaled anesthesia [3][4][5] Strategic Focus and Initiatives - **Continuous Improvement**: Launched Baxter GPS (Growth and Performance System) to enhance operational efficiency and drive growth [9][10] - **Capital Allocation**: Aiming to strengthen the balance sheet, targeting leverage under three times, and focusing on disciplined capital allocation for ongoing and future investments [8][15] - **Innovation**: Emphasis on new product development and extensions, with a shift in R&D spending towards innovation rather than sustaining engineering [21][22][25] Financial Performance and Goals - **Value Creators**: Focus on financial performance metrics such as revenue, margin, working capital, and return on invested capital (ROIC) [11][17] - **Market Growth**: Anticipates modest growth with a healthy pipeline of innovations, aiming to outperform low single-digit market growth [21][25] - **Dividend Strategy**: Reduced dividend to $0.01 to improve cash flow and pay down debt, with no immediate plans to change this [16][31] Challenges and Market Dynamics - **Market Conditions**: Facing a reset in baseline demand due to changes in clinical practices, particularly in the solutions business, with a noted 10%-15% demand decline relative to pre-hurricane levels [40][41] - **Product Issues**: Addressing challenges with the Novum pump, which is currently on hold due to safety concerns, while continuing to support the Spectrum pump line [34][36][37] Employee Engagement and Culture - **Mission-Driven Culture**: Strong alignment with the company's mission to save and sustain lives, fostering a culture of continuous improvement and employee engagement [44][45] - **Leadership Changes**: Recent leadership adjustments aimed at enhancing focus on critical areas of impact and driving the continuous improvement agenda [45] Conclusion Baxter International is positioned as a market leader in the MedTech industry, focusing on innovation, operational efficiency, and strategic capital allocation to drive growth and enhance shareholder value. The company is navigating challenges in market demand and product safety while fostering a strong internal culture aimed at continuous improvement and employee engagement [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45].

44th Annual J.P. Morgan Healthcare Conference Andrew Hider President & Chief Executive Officer January 12, 2026 1 Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results (including the company's net leverage target and estimated timing considerations) and operational, business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause a ...